Cargando…

Evaluation of serum interferons in patients with age-related macular degeneration

BACKGROUND: Environmental, genetic, and immunological factors may play a role in the pathogenesis of age-related macular degeneration (AMD). In an attempt to better understand the pathogenesis of AMD, in this study, we evaluated the serum interferon (IFN) levels in patients with AMD and compared it...

Descripción completa

Detalles Bibliográficos
Autores principales: Afarid, Mehrdad, Azimi, Ali, Malekzadeh, Mahyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450131/
https://www.ncbi.nlm.nih.gov/pubmed/31007694
http://dx.doi.org/10.4103/jrms.JRMS_363_18
_version_ 1783408980256620544
author Afarid, Mehrdad
Azimi, Ali
Malekzadeh, Mahyar
author_facet Afarid, Mehrdad
Azimi, Ali
Malekzadeh, Mahyar
author_sort Afarid, Mehrdad
collection PubMed
description BACKGROUND: Environmental, genetic, and immunological factors may play a role in the pathogenesis of age-related macular degeneration (AMD). In an attempt to better understand the pathogenesis of AMD, in this study, we evaluated the serum interferon (IFN) levels in patients with AMD and compared it with persons without AMD. MATERIALS AND METHODS: In this case–control study, 42 patients with AMD and 42 healthy individuals (without AMD) were enrolled as the case and control groups, respectively. The two groups were matched regarding their age and sex. We classified the case group as dry-type and wet-type AMD. Blood samples were obtained and the serum was collected and frozen at −20°C. Alpha-, beta-, and gamma-IFN levels were measured using the sandwich ELISA method and compared between and within the groups. RESULTS: The mean beta IFN levels in both case and control groups were 46.88 ± 27.25 pg/ml and 34.90 ± 18.81 pg/ml (P = 0.021), respectively. Regarding gamma and alpha IFN, the serum levels were not detectable in most of the patients and no significant difference was detected between the case and control groups. CONCLUSION: We found that serum beta IFN levels are higher in patients with AMD. This finding may have diagnostic, therapeutic, and prognostic value in AMD patients and can be a beginning for further evaluation.
format Online
Article
Text
id pubmed-6450131
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-64501312019-04-19 Evaluation of serum interferons in patients with age-related macular degeneration Afarid, Mehrdad Azimi, Ali Malekzadeh, Mahyar J Res Med Sci Short Communication BACKGROUND: Environmental, genetic, and immunological factors may play a role in the pathogenesis of age-related macular degeneration (AMD). In an attempt to better understand the pathogenesis of AMD, in this study, we evaluated the serum interferon (IFN) levels in patients with AMD and compared it with persons without AMD. MATERIALS AND METHODS: In this case–control study, 42 patients with AMD and 42 healthy individuals (without AMD) were enrolled as the case and control groups, respectively. The two groups were matched regarding their age and sex. We classified the case group as dry-type and wet-type AMD. Blood samples were obtained and the serum was collected and frozen at −20°C. Alpha-, beta-, and gamma-IFN levels were measured using the sandwich ELISA method and compared between and within the groups. RESULTS: The mean beta IFN levels in both case and control groups were 46.88 ± 27.25 pg/ml and 34.90 ± 18.81 pg/ml (P = 0.021), respectively. Regarding gamma and alpha IFN, the serum levels were not detectable in most of the patients and no significant difference was detected between the case and control groups. CONCLUSION: We found that serum beta IFN levels are higher in patients with AMD. This finding may have diagnostic, therapeutic, and prognostic value in AMD patients and can be a beginning for further evaluation. Wolters Kluwer - Medknow 2019-03-25 /pmc/articles/PMC6450131/ /pubmed/31007694 http://dx.doi.org/10.4103/jrms.JRMS_363_18 Text en Copyright: © 2019 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Afarid, Mehrdad
Azimi, Ali
Malekzadeh, Mahyar
Evaluation of serum interferons in patients with age-related macular degeneration
title Evaluation of serum interferons in patients with age-related macular degeneration
title_full Evaluation of serum interferons in patients with age-related macular degeneration
title_fullStr Evaluation of serum interferons in patients with age-related macular degeneration
title_full_unstemmed Evaluation of serum interferons in patients with age-related macular degeneration
title_short Evaluation of serum interferons in patients with age-related macular degeneration
title_sort evaluation of serum interferons in patients with age-related macular degeneration
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450131/
https://www.ncbi.nlm.nih.gov/pubmed/31007694
http://dx.doi.org/10.4103/jrms.JRMS_363_18
work_keys_str_mv AT afaridmehrdad evaluationofseruminterferonsinpatientswithagerelatedmaculardegeneration
AT azimiali evaluationofseruminterferonsinpatientswithagerelatedmaculardegeneration
AT malekzadehmahyar evaluationofseruminterferonsinpatientswithagerelatedmaculardegeneration